Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Lttl vs Primary Clinic (Direct GLP)

Lttl
Graded #204

Higher grade

vs+0.5999999999999943
Primary Clinic (Direct GLP)
Graded #219

Lower grade

The verdict

Lttl takes it — 66.1/100 to 65.5/100, but only just.

Lttl grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lttl (pronounced 'little') is a direct-to-consumer telehealth brand offering compounded semaglutide and tirzepatide, a low-dose 'microdose' line, and longevity peptides. Primary Clinic (Direct GLP) is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePrimary Clinic (Direct GLP) +9
56
65
Dose & formulationLttl +42
96
54
Clinical oversightLttl +1
76
75
Labs & monitoringPrimary Clinic (Direct GLP) +24
52
76
FulfillmentPrimary Clinic (Direct GLP) +4
69
73
Contract termsPrimary Clinic (Direct GLP) +21
20
41
Lttl · left barPrimary Clinic (Direct GLP) · right bar

The numbers

MetricLttlPrimary Clinic (Direct GLP)
WeighScore66.1/10065.5/100
GradeCC
Scorecard rank#204#219
Semaglutide$199/mo (all doses, compounded)$85/mo (0.25-0.75 mg band, membership required, compounded)
Tirzepatide$279/mo (all doses, compounded)$133/mo (1.25-2.5 mg band, membership required, compounded)
CoverageCoverage not published10 states
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
Lttl

Graded #204 · C

Strengths

  • Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
  • Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
  • States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
  • Microdose line prices low-dose semaglutide or tirzepatide at $149/mo month-to-month for people sensitive to side effects
  • Oral ODT semaglutide offered for members who want to avoid injections

Where it loses points

  • Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
  • The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
  • No public list of states served — eligibility depends on where unnamed 'partner providers are licensed'
  • Site banner promises 'Prescribed and shipped within 48 hours' while the shipping policy states 2-5 business days to process plus 3-7 to deliver
  • Medications cannot be returned or refunded once they ship from the pharmacy

Strengths

  • Direct Primary Care model integrates GLP-1 with continuous primary care — unlike most direct-to-consumer platforms
  • GLP-1 at wholesale cost with no markup — semaglutide from $65/mo, tirzepatide from $110/mo (members only)
  • Unlimited primary care visits, direct text access, and same-day care bundled in the $89/mo membership
  • Routine labs and thousands of medications included in membership — no surprise bills
  • Per-dose pricing shown publicly for all 8 dose tiers of both semaglutide and tirzepatide

Where it loses points

  • The medication price is on top of an $89/mo direct-primary-care membership, which the FAQ states does not include the drug — all-in is about $174/mo for semaglutide and $222/mo for tirzepatide
  • Prices are published as dose BANDS rather than per dose, and the cheapest tirzepatide band starts at 1.25 mg, below the 2.5 mg labelled starting dose
  • The pricing is rendered entirely in JavaScript, so nothing on the page is readable without running the site's bundle
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard